Disclaimers and Forward-Looking Statements

This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. The results of earlier clinical trials may not be predictive of future results. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aldeyra’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect Aldeyra’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including the development, clinical and regulatory plans or expectations for Aldeyra’s product candidates and Aldeyra’s continuing review and quality control analysis of clinical data. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements are described in Aldeyra’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as Aldeyra’s subsequent filings with the Securities and Exchange Commission. All of Aldeyra’s development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the initiation, completion, or reporting of clinical trials.

In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this presentation is provided only as of October 31, 2019, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
The Prevalence and Economic Burden of Allergic Conjunctivitis is Rising

Allergic diseases are hyperendemic and prevalence is increasing

Allergic conjunctivitis affects more than 1 billion people worldwide, including 100 million in the U.S.

Temperatures and CO₂ levels are rising

Allergy seasons are getting longer and more severe

Pollen is spreading to new areas

Millions of patients continue to suffer and new treatments are needed

Physicians and Patients Say That Currently Available Treatments Are Inadequate

Up to 30 million of allergic conjunctivitis sufferers in the U.S. do not respond adequately to or are dissatisfied with antihistamines.

Antihistamines are not effective in an estimated 24% of treated allergic conjunctivitis patients.

Many allergic conjunctivitis patients make significant sacrifices due to lack of drug activity.

Nearly 1 in 5 of allergic conjunctivitis patients are using corticosteroid and/or NSAID eye drops*.

The allergic conjunctivitis patient population is underserved, and novel therapies are in demand.

*IQVIA analysis of diagnosed AC patients utilizing topical ocular Rx treatments. Source: Aldeyra internal estimates based on primary and secondary market research; published literature
Reproxalap’s Novel Mechanism of Action Has The Potential to Provide Differentiated Activity Versus Antihistamines

- Reproxalap irreversibly inhibits RASP, limiting allergic inflammation.
- Reproxalap has the potential to be uniquely effective in post-histaminic allergy, which affects all allergic conjunctivitis patients.

**Reproxalap**

- Scavenger Receptor A
- NFκB pathway
- Inflammasome activation

**Histaminic Phase** (minutes)
- Degranulation: release of histamine & other inflammatory mediators
- Increasing Allergy Symptoms

**Post-Histaminic Phase** (builds over hours)
- Inflammatory cell recruitment
- RASP
- Cell activation

**RASP** = Reactive Aldehyde Species
The Allergen Chamber is Designed to Mimic Real-World Exposure to Airborne Allergens With Control and Consistency

Clinical Model Comparison
For Allergic Conjunctivitis Clinical Trial Design

**Allergen Field Study**

*Patients administer drug at home during allergy season and maintain a journal.*

- ✓ Real-world exposure to allergen
- ✓ Repeated exposure to allergen throughout study
- ✗ Uncontrolled allergen content and concentration
- ✗ Variable participant behavior

**Conjunctival Allergen Challenge**

*Investigator administers one drop of allergen mixture on to conjunctiva and records results.*

- ✓ Specified allergen content and concentration
- ✓ Participants observed and assisted by investigator
- ✗ Artificial allergen exposure
- ✗ Single exposure limitation

**Allergen Chamber**

*Investigator monitors and assists patients in a controlled allergen chamber.*

- ✓ Real-world exposure to allergen
- ✓ Specified allergen content and concentration
- ✓ Repeated exposure to allergen throughout study
- ✓ Participants observed and assisted by investigator
- ✓ Assessment of prophylaxis and treatment
The Allergen Chamber:
A Demanding Real-World Drug Assessment in Allergic Conjunctivitis

• To our knowledge, no late-stage investigational allergic conjunctivitis drug has been rigorously tested in an allergen chamber.

• The allergen chamber enables a controlled, environmental allergen exposure that mimics real-world exposure to airborne allergens.

• Subjects are exposed to allergen continuously for approximately 3.5 hours.

• Subject-reported ocular itch and tearing scores, and investigator-assessed redness scores, are obtained approximately every 10 minutes.

• Drug or vehicle is administered prior to allergen exposure and at 90 minutes, when peak symptoms typically occur.

• The chamber allows for detailed assessment of prophylaxis and treatment with unparalleled standardization.
Reproxalap Allergen Chamber Clinical Trial Design*

- **Primary objective:**
  - Evaluate efficacy of reproxalap ophthalmic solution vs. vehicle to confirm dosing regimen and sample size for Phase 3 clinical testing

- **Inclusion/exclusion criteria:**
  - History of moderate to severe allergic conjunctivitis to ragweed pollen
  - Itching score of $\geq 2.5$ or redness score $\geq 2$ in baseline chamber test

- **Endpoints:**
  - Patient-reported ocular itch score and tearing score
  - Investigator-assessed ocular redness score
  - Total ocular symptom score

*The reproxalap allergen chamber clinical trial was a Phase 1/2 methods development study. Further information can be found on www.clinicaltrials.gov: Trial #NCT03709121.*
Reproxalap Showed Greater and More Durable Clinical Responses Than Vehicle in Allergen Chamber Clinical Trial

**Ocular Itch Score (0-100) During 3.5 Hours of Allergen Exposure**

- **MMRM p < 0.0001**

**Ocular Redness Score (0-4) During 3.5 Hours of Allergen Exposure**

- **MMRM p < 0.0001**

**Statistically significant reduction in ocular itch vs. vehicle for more than three hours of exposure to allergen**

**Statistically significant reduction in ocular redness vs. vehicle for more than three hours of exposure to allergen**

Source: Aldeyra Therapeutics allergen chamber clinical trial – reproxalap 0.25% (ClinicalTrials.gov #NCT03709121); n=66

MMRM = Mixed Effect Model Repeated Measures
Reproxalap Demonstrated Prophylactic and Treatment Activity in Allergen Chamber Clinical Trial

Total Ocular Symptom Score (0-11 scale) During 3.5 Hours of Allergen Exposure

MMRM p < 0.0001

Statistically significant reduction in all assessed ocular symptoms and signs (itch, redness, and tearing) for more than three hours of exposure to allergen.

Source: Aldeyra Therapeutics allergen chamber clinical trial – reproxalap 0.25% (ClinicalTrials.gov #NCT03709121); n=66

MMRM = Mixed Effect Model Repeated Measures
Relative to Vehicle Treatment, Fewer Reproxalap-Treated SubjectsReached Sustained Ocular Itch Scores \(\geq 2\) in Allergen Chamber Clinical Trial

Development of sustained ocular itch scores of greater than or equal to 2 (scale 0 – 4) was slower and less frequent in repoxalap-treated subjects than in vehicle-treated subjects, supporting the clinical relevance of the itch score results.

*Time to response analysis baseline adjusted, p-value of log-rank analysis.
Source: Aldeyra Therapeutics allergen chamber clinical trial – reproxalap 0.25% (ClinicalTrials.gov #NCT03709121); n=66
Reproxalap Was Generally Well Tolerated and No Safety Concerns Were Observed in Allergen Chamber Clinical Trial

- No observed safety or tolerability concerns
- Most common treatment-emergent event was transient instillation site irritation
- No observed findings on safety assessments:
  - Visual Acuity (ETDRS chart)
  - Intraocular pressure (contact tonometry)
  - Slit lamp biomicroscopy
  - Dilated fundoscopy
- Topical ocular reproxalap has now been administered to over 1,000 patients across twelve clinical trials.
The INVIGORATE Phase 3 Clinical Trial Design

- **Primary endpoint:**
  - Statistical significance in ocular itch (0-4 scale) at a majority of eleven time points between 110 and 210 minutes

- **Secondary endpoints:**
  - Investigator-assessed ocular redness score
  - Patient-reported ocular tearing score
  - Total ocular symptom score

- **Inclusion/exclusion criteria:**
  - Same as prior allergen chamber trial

- **Dosing schedule and chamber exposure:**
  - Same as prior allergen chamber trial

Agreement on trial design and primary endpoint reached with FDA on October 1, 2019.

Contingent on funding, clinical results, regulatory review, and other factors.
Confirmed INVIGORATE Phase 3 Primary Endpoint Achieved in Allergen Chamber Clinical Trial*

*The safety and efficacy results of later phase or subsequent clinical trials may not confirm the results of earlier trials; p-value derived from Mixed effect Model Repeat Measurement (MMRM) time point analyses.

Source: Aldeyra Therapeutics allergen chamber clinical trial – reproxalap 0.25% (ClinicalTrials.gov #NCT03709121); n=66

### Ocular Itching Score (0-4) During 3.5 Hours of Allergen Exposure

- **First Dose**: 5 min before chamber entry
- **Second Dose**: 105 min after chamber entry
- **Primary Endpoint Assessment Period** for Statistical Significance of Majority of Time Points

<table>
<thead>
<tr>
<th>Allergen chamber time point</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>112</td>
<td>0.0002</td>
</tr>
<tr>
<td>122</td>
<td>0.0004</td>
</tr>
<tr>
<td>132</td>
<td>0.0002</td>
</tr>
<tr>
<td>142</td>
<td>0.0044</td>
</tr>
<tr>
<td>152</td>
<td>0.0001</td>
</tr>
<tr>
<td>172</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>192</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>212</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

All time points from 110 to 210 minutes were statistically significant in allergen chamber trial.
INVIGORATE Phase 3 Trial Design And Primary Endpoint Confirmed

Positive Allergen Chamber Clinical Trial Results

- Reproxalap showed greater and durable clinical responses vs. vehicle
  - Statistically significant reduction in ocular itch ($p < 0.0001$), ocular redness ($p < 0.0001$), and total ocular symptoms score ($p < 0.0001$)
- Reproxalap demonstrated prophylaxis and treatment activity for more than three hours of continuous allergen exposure
- Clinical relevance of itch score results supported by responder analysis
  - Less frequent development of sustained ocular itch score $\geq 2$ in reproxalap-treated subjects vs. vehicle (0-4 scale)

INVIGORATE Phase 3 Clinical Trial

- Design and primary endpoint agreement with FDA on October 1, 2019
  - Dosing schedule and chamber exposure same as prior allergen chamber trial
  - Phase 3 primary endpoint defined as statistical significance in ocular itching at a majority of time points over a pre-specified range
  - Confirmed primary endpoint achieved in prior allergen chamber clinical trial*

Expected to initiate H1 2020

*The safety and efficacy results of later phase or subsequent clinical trials may not confirm the results of earlier trials.
# Upcoming and Recently Achieved Development Milestones:

**Novel Approaches to Address Immune-Mediated Disease**

- **Reproxalap allergic conjunctivitis design for** INVIGORATE Phase 3 **confirmed October 2019**
- **ADX-2191 proliferative vitreoretinopathy** GUARD Phase 3 - Part 1 clinical trial initiation Q4 2019
- **ADX-1612 post-transplant lymphoproliferative disorder** Phase 2 clinical trial initiation H2 2019
- **Reproxalap dry eye disease** RENEW Phase 3 - Part 1 completion Q4 2019
- **Reproxalap allergic conjunctivitis** INVIGORATE Phase 3 initiation H1 2020

- **ADX-629 systemic** Phase 1 clinical trial initiation H2 2019
- **Reproxalap Sjögren-Larsson Syndrome** RESET Phase 3 - Part 1 completion Q2 2019
- **Positive** reproxalap allergic conjunctivitis **allergen chamber trial top-line results**
- **Reproxalap dry eye disease** RENEW Phase 3 - Part 1 clinical trial initiation April 2019
- **Positive** reproxalap allergic conjunctivitis ALLEVIATE Phase 3 trial results March 2019

*Contingent on funding, regulatory review, clinical results and other factors*